Sage Journals: Discover world-class research

Abstract

The coronavirus disease 2019 (COVID‐19) outbreak caused by the 2019 novel coronavirus (2019-nCOV) is becoming increasingly serious. In March 2019, the Food and Drug Administration (FDA) designated remdesivir for compassionate use to treat COVID-19. Thus, the development of novel antiviral agents, antibodies, and vaccines against COVID-19 is an urgent research subject. Many laboratories and research organizations are actively investing in the development of new compounds for COVID-19. Through in silico high-throughput virtual screening, we have recently identified compounds from the compound library of Natural Products Research Laboratories (NPRL) that can bind to COVID-19 3L^pro polyprotein and block COVID-19 3L^pro activity through in silico high-throughput virtual screening. Curcuminoid derivatives (including NPRL334, NPRL339, NPRL342, NPRL346, NPRL407, NPRL415, NPRL420, NPRL472, and NPRL473) display strong binding affinity to COVID-19 3L^pro polyprotein. The binding site of curcuminoid derivatives to COVID-19 3L^pro polyprotein is the same as that of the FDA-approved human immunodeficiency virus protease inhibitor (lopinavir) to COVID-19 3L^pro polyprotein. The binding affinity of curcuminoid derivatives to COVID-19 3L^pro is stronger than that of lopinavir and curcumin. Among curcuminoid derivatives, NPRL-334 revealed the strongest binding affinity to COVID-19 3L^pro polyprotein and is speculated to have an anti-COVID-19 effect. In vitro and in vivo ongoing experiments are currently underway to confirm the present findings. This study sheds light on the drug design for COVID-19 3L^pro polyprotein. Basing on lead compound development, we provide new insights on inhibiting COVID-19 attachment to cells, reducing COVID-19 infection rate and drug side effects, and increasing therapeutic success rate.

Keywords

curcuminoid derivatives 2019‐nCoV Natural Products Research Laboratories compound library

In December 2019, several unexplained and very serious cases of pneumonia were reported in Wuhan, China.^{^1,2} Many governments and researchers worldwide carried out investigations.^3

-6 On February 11, 2020, the World Health Organization named the disease caused by the 2019 novel coronavirus (2019‐nCoV) as coronavirus disease 2019 (COVID‐19).^7,8 As of July 23, 2020, more than 15 1000 000 cases and 620 000 deaths have been reported around the world (https://www.cdc.gov.tw/En). Coronaviruses are a family of viruses that target the respiratory system of humans.^9,10 Previous outbreaks of coronavirus (CoV) infection include severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome-CoV.^11,12 CoVs are positive-sense single-stranded ribonucleic acid (RNA) viruses containing glycoproteins on the envelope. In human hosts, CoVs cause a wide array of respiratory, body infection, gastrointestinal, neurological, and brain diseases.^13,14 A genomic analysis of 2019‐nCoV in a COVID-19 patient from Wuhan, China, revealed a nucleotide identity of 89% to bat SARS-like-CoVZXC 21% and 82% to human SARS-CoV.¹⁵ The single-stranded RNA genome of 2019‐nCoV contains 29 891 nucleotides that encode for 9860 amino acids.^8,16 Studies showed that 2019‐nCoV invades and infects human lung cells through the receptor angiotensin-converting enzyme II (ACE2).^17,18

The following antiviral agents against 2019-nCoV may represent suitable therapy options: (1) ACE2 receptor antagonist blocks coronavirus-host interactions and attachments^19,20; (2) favipiravir and remdesivir inhibit RNA-dependent RNA polymerase; (3) Kaletra (lopinavir/ritonavir) suppresses main protease protein COVID-19 3CL^pro polyprotein^21,22; (4) lysosomotropic base chloroquine phosphate disrupts intracellular trafficking and viral fusion events^23,24; (5) ribavirin interferes with RNA metabolism required for viral replication²⁵; (6) vaccine and immunotherapeutic agents (interferon [IFN]-α, pegylated interferon alfa-2a and -2b).^3,25
-27 On March 23, 2020, the Food and Drug Administration (FDA) designated remdesivir for compassionate use to treat COVID-19. RNA-dependent RNA polymerase inhibitors appear nonspecific, display low potency, and cause common adverse reactions in patients.^28
-30 ACE2 receptor antagonist agents have significant adverse reactions and are not advanced clinically.^31,32 However, the FDA has yet to approve remdesivir for coronavirus treatment. Nevertheless, drug repurposing of remdesivir as a promising antiviral agent against COVID-19 and clinical trials are currently underway to determine the complete efficacy of the compound in patients (clinicaltrials.gov, NCT04280705).^26,33 In addition, COVID-19 patients administered with Kaletra (lopinavir/ritonavir; a protease inhibitor) have improved health outcomes, suggesting the potential of the main protease (COVID-19 3CL^pro) as an important target in COVID-19 therapy.^22,26

Curcumin (1,7-bis[4-hydroxy 3-methoxy phenyl]−1,6-heptadiene-3,5-dione) is a polyphenolic compound found in the rhizome of Curcuma longa (usually known as turmeric). Curcumin has been used as a traditional Chinese medicine and as a coloring and flavoring agent in Taiwan, China, and India, and it is increasingly recognized as a potential therapeutic agent.^34
-36 Curcumin is used to treat various disorders, including chronic diseases, inflammatory disorders, and infection, because of its several bioactivities, including antioxidant, anti-inflammatory, and immune-regulatory activities; preventive effects against cancers and diabetes; and protective effects on the liver, brain, and nervous and cardiovascular systems.³⁷ Curcumin can also fight against herpes simplex virus,³⁸ Zika virus,³⁹ Epstein-Barr virus,⁴⁰ human immunodeficiency virus (HIV),^41,42 and respiratory syncytial viruses, such as tobacco mosaic virus and cucumber mosaic virus.^43

-46 The antivirus activity of curcumin includes protease inhibition in HIV.^47,48 Recently, curcumin has been demonstrated to block the entry of COVID-19.^49
-51

Molecular docking techniques aim to predict the best matching binding mode of a ligand to a macromolecular partner, which plays a central role in all biological processes.⁵² The present study aimed to determine whether COVID-19 3CL^pro can be a major target protein with strong binding affinities to lopinavir, curcumin, and compounds from the compound library of Natural Products Research Laboratories (NPRL) by molecular docking techniques. Our results demonstrated that all curcuminoid derivatives from the NPRL compound library could form H-bonds or hydrophobic interactions with COVID-19 3CL^pro residues among His3304, Cys3408, Met3428, Pro3431, Gln3452, and Glu3429. NPRL342 has the best docking performance by CDOCKER, suggesting that NPRL342 has a more stable docked structure than lopinavir and curcumin.

Materials and Methods

Collection of Data Set in Compounds of NPRL

The NPRL compound library is a collaboration between Professor Kuo-Hsiung Lee’s NPRL of the University of North Carolina and China Medical University Hospital to share these natural products and their synthesized derivatives. More than 3000 compounds have been produced by Professor Lee and the researchers in NPRL. In this study, curcumin and lopinavir (an antiretroviral protease inhibitor) were selected as positive ligand molecules from the compounds of NPRL from the in-house database. A 2-dimensional (2D)-3D conversion of images was generated using the Discovery Studio 2020 program (DS 2020), followed by energy minimization using the Smart Minimizer algorithm in the CHARMm force ﬁeld (Dassault Systemes BIOVIA, Discovery Studio Modeling Environment, Release 2020, San Diego, CA, USA: Dassault Systemes, 2020). These minimized molecules were subjected to the following molecular docking experiments. An experimental design was created to discover the potential compound for binding COVID-19 3CL^pro polyprotein in in silico studies. The experimental process includes sequence alignment for determining similar regions between the SARS-CoV 3CL^pro sequence and the COVID-19 3CL^pro polyprotein orf1ab sequence. COVID-19 3CL^pro homology models were constructed, and the best homology model among all generated models was selected. Database compounds from the NPRL compound library were prepared. Ligand binding site and molecular docking were defined. The binding interaction and residue in each binding pose were compared. The top 9 ranked compounds in the database were selected for further analysis (Figure 1).

Figure 1

Experimental design to discover potential compounds for binding COVID-19 3CL^pro polyprotein in silico study. Details in text. COVID-19, coronavirus disease 2019; NPRL, Natural Products Research Laboratories; SARS-CoV, severe acute respiratory syndrome-coronavirus.

Homology Modeling

The template structure of SARS-CoV 3CL^pro and the target protein sequence of COVID-19 3CL^pro polyprotein orf1ab were obtained from the Protein Data Bank (PDB code: 2ZU4) and the GenBank (Accession: YP_009724389.1), respectively. Subsequently, sequence alignment in DS 2020 was applied to align the polyprotein sequence of SARS-CoV 3CL^pro with the polyprotein orf1ab sequence of COVID-19 3CL^pro. The best-aligned region in COVID-19 3CL^pro polyprotein orf1ab to SARS-CoV M^pro was then used to generate COVID-19 3CL^pro polyprotein homology models in accordance with the Build Homology Models protocol. Finally, the qualities of generated homology models were examined with the discrete optimized potential energy (DOPE) score. The homology model with the lowest DOPE score was selected for the docking calculation.

Molecular Docking

The binding site of COVID-19 3CL^pro was identified by homology comparison to this study. After energy minimization, the molecules were docked into COVID-19 3CL^pro by using the CDOCKER protocol embedded in DS 2020. For each molecule, 9 docking poses were generated and ranked using the CDOCKER score (-CDOCKER interaction energy). On the basis of the CDOCKER score, from the top 9 Hits of compounds from NPRL in the in-house database, curcumin and lopinavir were selected for further binding interaction analysis.

Results

Construction of COVID-19 3CL^pro Homology Models

Before the COVID-19 3CL^pro homology models were constructed, COVID-19 3CL^pro polyprotein orf1ab residues 3264-3569 were aligned with a template sequence of SARS-CoV 3CL^pro in accordance with the sequence alignment protocol in DS 2020. Sequence alignment shows that the sequence identity and sequence similarity between SARS-CoV 3CL^pro and COVID-19 3CL^pro are 96% and 99%, respectively (Figure 2). On the basis of the sequence alignment results, 10 models were built using the Build Homology Models protocol in DS 2020 and ranked with the DOPE score value. The most suitable COVID-19 3CL^pro homology model for docking was selected based on the lowest DOPE score (−34992.3), as shown in Figure 3A. As shown in Figure 3B, 99.3% (302/304) of residues fall in either favored or allowed regions of the Ramachandran plot, suggesting that the backbone conformation predictions from the homology model were within the normal range. With these substantial validation results, our homology model can be used for molecular docking.

Figure 2

Best sequence alignment area of COVID-19 3CL^pro polyprotein orf1ab with the crystal structure of SARS-CoV M^pro (protien data bank code: 2ZU4). COVID-19, coronavirus disease 2019; SARS-CoV, severe acute respiratory syndrome-coronavirus.

Figure 3

(A) Most suitable COVID-19 3CL^pro homology model obtained in our study. The protein structures are shown as solid ribbon. (B) The Ramachandran phi-psi diagram is used to calculate for the COVID-19 3CL^pro homology model. COVID-19, coronavirus disease 2019.

Molecular Docking

All molecules were docked into the binding site of the COVID-19 3CL^pro homology model by using the CDOCKER protocol to determine the binding affinities of curcumin and lopinavir to COVID-19 3CL^pro. The top 9 Hits from the in-house database were achieved based on their CDOCKER score: NPRL342 (Figure 4), NPRL415 (Figure 5), NPRL339 (Figure 6), NPRL346 (Figure 7), NPRL407 (Figure 8), NPRL420 (Figure 9), NPRL472 (Figure 10), NPRL334 (Figure 11), and NPRL473 (Figure 12). All compounds are curcuminoid derivatives. The most suitable docking site for each compound shown in Figure 13 shows a similar binding position to that of lopinavir. The detailed docking results of the top 9 Hits (Table 1 and Figures 5 -15), lopinavir (Figure 14), and curcumin (Figure 15) with COVID-19 3CL^pro are listed in Table 1. As shown in Table 1, all compounds could form H-bonds or hydrophobic interactions with residues among His3304, Cys3408, Met3428, Pro3431, Gln3452, and Glu3429 (Figures 5 -15). In addition, NPRL342 has the best docking performance by CDOCKER (Figure 4), suggesting that NPRL342 has a more stable docked structure than lopinavir (Figure 14) and curcumin (Figure 15). The 2D and 3D interaction diagrams of NPRL342 shown in Figure 4 verify the understanding of the interactions between NPRL342 and COVID-19 3CL^pro. For NPRL342, multiple H-bond interactions formed with residues His3304, Phe3403, Glu3429, His3427, Gln3452, Asn3405, and Thr3453. In addition, the alkyl and aromatic ring groups participated in hydrophobic interactions with residues Cys3408, His3304, Met3428, Leu3430, and Pro3431 (Figure 4). Docking results show that NPRL342 plays a key role in H-bond and hydrophobic interactions with crucial residues in the binding site of COVID-19 3CL^pro, suggesting that NPRL342 has a similar binding affinity to SARS-CoV M^pro compared with lopinavir.

Figure 4

NPRL342 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL342. (B) Best docking pose of NPRL342 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL342 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 5

NPRL415 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL415. (B) Best docking pose of NPRL415 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL415 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 6

NPRL339 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL339. (B) Best docking pose of NPRL339 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL339 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 7

NPRL346 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL346. (B) Best docking pose of NPRL346 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL346 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 8

NPRL407 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL407. (B) Best docking pose of NPRL407 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL407 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 9

NPRL420 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL420. (B) Best docking pose of NPRL420 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL420 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 10

NPRL472 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL472. (B) Best docking pose of NPRL472 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL472 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 11

NPRL334 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL334. (B) Best docking pose of NPRL334 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL334 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 12

NPRL473 selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of NPRL473. (B) Best docking pose of NPRL473 with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of NPRL473 with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 13

Overlap of ligand binding surfaces and the protein surface. The best binding pose for each compound is in blue. The best binding pose for lopinavir is in purple. The protein surface is in gray. NPRL, Natural Products Research Laboratories.

Figure 14

Lopinavir selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of lopinavir. (B) Best docking pose of lopinavir with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of lopinavir with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Figure 15

Curcumin selectively targets the COVID-19 3CL^pro binding site. (A) 2D structure of curcumin. (B) Best docking pose of curcumin with COVID-19 3CL^pro. (C) 2D ligand interaction diagram of curcumin with COVID-19 3CL^pro. COVID-19, coronavirus disease 2019; 2D, 2 dimensional; NPRL, Natural Products Research Laboratories.

Table 1

The Docking Results of 9 Hits From NPRL Compounds, Curcumin, and Lopinavir With COVID-19 3CL^pro.

Name	CDOCKER score	Number of H-bonds	Number of hydrophobics	Interaction residues
Lopinavir	55.6920	10	7	Ala3454, Gln3452, His3304, Leus3430, Met3428, Pro3431, Cys3408, Met3312, Glu3429
Curcumin	43.2855	7	4	Ala3454, Gln3452, His3304, Gln3455, His3426, Pro3431, His3427, Thr3453
NPRL342	64.4062	12	8	Glu3429, His3304, Phe3403, His3427, Gln3452, Asn3405, Thr3453, Met3428, Cys3408, Leu3430, Pro3431
NPRL415	61.4095	10	1	His3304, Asn3405, Cys3408, Gln3452, Thr3288
NPRL339	58.3537	6	6	Asn3405, Cys3408, Ala3454, His3426, His3435, Glu3429, Glu3455, Thr3288, Thr3289, Pro3431, Met3312
NPRL346	57.2150	12	6	Glu3429, Gln3452, Met3428, Gln3455, Asp3450, Phe3403, Leu3404, Pro3431, Met3312, His3304
NPRL407	56.3007	6	1	Asn3405, Leu3404, Gln3452, Glu3429, Thr3453, Asp3450
NPRL420	56.1476	8	3	His3426, Cys3408, Asn3405, Glu3429, Thr3453, Gln3452, Pro3431, Met3428
NPRL472	55.6795	6	8	Pro3431, Cys3407, Met3312, Leu3404, Glu3429, Asp3450, Gln3452, His3304 , Met3428, Pro3431
NPRL334	54.8665	8	7	Glu3429, Met3428, Ala3454, His3304, His3426, Gln3452, Leu3404, Thr3289, Gln3455, Pro3431, Leu3290
NPRL473	54.7874	5	10	Ala3454, Met3428, Pro3431, Glu3429, Phe3403, Cys3408, His3304, His3426, His3435, Met3312, Met342 Cys3408, Thr3288

Abbreviations: COVID-19, coronavirus disease 2019; 2D, 2-dimensional; NPRL, Natural Products Research Laboratories.

The bold letters: It is the same interaction residues with curcumin.

Discussion

Since the outbreak of COVID-19 pneumonia, the number of confirmed cases and deaths has increased in various countries, which has a great impact on medical, economic, and social activities around the world.^1,2,5,8 The prevention and treatment of COVID-19 infection are important in current medical research.^53
-55 Medical research scientists around the world are continuing to work day and night. According to many private estimates from the Chinese government, the number of COVID-19-infected Indians evacuated from China is 0, which may be related to their eating habits. Curry, which is the staple food of Indians, contains a large amount of curcumin and curcuminoids.^56,57 Previous reports have indicated that curcumin and curcuminoids exhibit antiviral, antibacterial, anticancer, and regulating immune response abilities.^36,58,59 Curcumin and related supplement nanoparticles are useful agents to help treat HIV infection.^42,60,61 Antiviral effects of curcumin include (1) inhibiting the attachment of the gp-120 protein to T cells^62,63; (2) blocking virus protease activity^64

-67; (3) reducing tissue inflammation and inflammatory molecules (interleukins, tumor necrosis factor-α, nuclear factor kappa-light-chain-enhancer of activated b cells, and cyclooxygenase-2 release)^47,68; (4) increasing the antiviral effect of splenic IFN-γ and regulatory T cells,⁴⁷ and (5) increasing natural killer cell activation.⁶⁹ In the present study, DS 2020 software was used for the first time to screen the NPRL compound library. Our results showed that curcumin (Figure 15) and curcuminoid derivatives, including NPRL342 (Figure 4), NPRL415 (Figure 5), NPRL339 (Figure 6), NPRL346 (Figure 7), NPRL407 (Figure 8), NPRL420 (Figure 9), NPRL472 (Figure 10), NPRL334 (Figure 11), and NPRL473 (Figure 12), have strong binding abilities to COVID-19 3CL^pro protease. The exact position shares the clinically used HIV protease inhibitor lopinavir (Figure 14). Recently, curcumin has been demonstrated to block the entry of COVID-19 and viral protease, as well as modulating various cellular signaling pathways.⁵⁰ Curcumin and lopinavir could form H-bonds or hydrophobic interactions in common with residues among Ala3454, Gln3452, His3304, and Pro3431 of COVID-19 3CL^pro. Lopinavir and selected curcuminoids from the NPRL compound library could form H-bonds or hydrophobic interactions with residues among Ala3454, Gln3452, His3304, Leu3430, Met3428, Pro3431, Cys3408, Met3312, and Glu3429 of COVID-19 3CL^pro protease (Table 1 and 5 -15). NPRL342 has the best docking performance by CDOCKER, suggesting that NPRL342 may be a more potent agent against COVID-19 3CL^pro protease than lopinavir and curcumin. Further experiments will be performed to confirm the anti-COVID-19 viral activity of the potential lead compounds. Residues located on Ala3454, Gln3452, His3304, Gln3455, His3426, Pro3431, His3427, and Thr3453 of COVID-19 3CL^pro are crucial positions for binding curcumin and curcuminoid derivatives from the NPRL compound library (Table 1). These residues are labeled in red. Our preliminary result demonstrated that curcumin inhibits COVID-19 RNA-dependent RNA polymerase (RdRp) activity. In addition, related experiments will be performed to confirm the anti-COVID-19 viral activity of the potential lead compounds. We look forward to discovering new and effective agents as soon as possible for providing clinical trials to reduce the infectivity of COVID-19 and treat COVID-19.

Among the many potential targets against SARS-CoV and other CoVs, protease is highly conserved.⁷⁰ Protease inhibitors can prevent virus replication and proliferation through interfering with the post-translational processing of viral polypeptides.^70,71 Lopinavir is an HIV-1 protease inhibitor capable of inhibiting SARS-CoV M^pro.^21,72,73 In Figure 2, the COVID-19 3CL^pro homology model shows that the sequence identity and sequence similarity between SARS-CoV 3CL^pro and COVID-19 3CL^pro are 96% and 99%, respectively. Our results suggest that COVID-19 3CL^pro can be used as a homologous target for screening compounds that inhibit the replication and proliferation of 2019-nCoV.

In the future, we will conduct in vitro and in vivo experiments to confirm the findings of our in silico studies. We will also use DS 2020 software and Synthia Organic Retrosynthesis Software for the structure optimization to de novo synthesize the most effective compounds for COVID-19 in our artificial-intelligence-based drug discovery platform. Related experiments will be performed to confirm the anti-COVID-19 viral activity of the potential lead compounds. We look forward to discovering new and effective agents as soon as possible for providing clinical trials to reduce the infectivity of COVID-19 and treat COVID-19 pneumonia.

Footnotes

Acknowledgments

We wish to acknowledge the work of Mr Cheng-Li Chou, Yu-Hsun Cheng, and Wain-Ling Huang (VtR Incorporated, Taipei, Taiwan) for the excellent technique and equipment support in this study.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the project from the compound library of Natural Products Research Laboratories (NPRL) of China Medical University Hospital (CMUH) and University of North Carolina (UNC), Chapel Hill Eshelman School of Pharmacy. This work was also supported by a grant from China Medical University Hospital, Taichung, Taiwan (DMR-109-147).

ORCID iDs

Jai-Sing Yang

Jo-Hua Chiang

References

Zhao

W-M.

Song

S-H.

Chen

M-L

et al. The 2019 novel coronavirus resource. Yi Chuan. 2020;42(2):212-221.doi:10.16288/j.yczz.20-030

http://www.ncbi.nlm.nih.gov/pubmed/32102777

Containing

KEH

. 2019-nCoV (Wuhan) coronavirus. Health Care Manag Sci. 2020;23(3):311-314.

Lippi

Simundic

A-M.

Plebani

. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 2020;58(7):1070-1076.doi:10.1515/cclm-2020-0285

http://www.ncbi.nlm.nih.gov/pubmed/32172228

Nelson

. COVID-19: time for who to reconsider its stance towards Taiwan. Nature. 2020;579(7798):193 doi:10.1038/d41586-020-00693-2

http://www.ncbi.nlm.nih.gov/pubmed/32157235

Y-C.

Chen

C-S.

Chan

Y-J

. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020;83(3):217-220.doi:10.1097/JCMA.0000000000000270

http://www.ncbi.nlm.nih.gov/pubmed/32134861

Huang

W-H.

Teng

L-C.

Yeh

T-K

et al. 2019 novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J Microbiol Immunol Infect. 2020;53(3):481-484.doi:10.1016/j.jmii.2020.02.009

http://www.ncbi.nlm.nih.gov/pubmed/32111449

Cucinotta

Vanelli

. Who declares COVID-19 a pandemic. Acta Biomed. 2020;91(1):157-160.doi:10.23750/abm.v91i1.9397

http://www.ncbi.nlm.nih.gov/pubmed/32191675

Cascella

Rajnik

Cuomo

Dulebohn

SC.

Di Napoli

. Features, evaluation and treatment of coronavirus (COVID-19). StatPearls. 2020

Liew

MF.

Siow

WT.

Yau

YW.

See

. Safe patient transport for COVID-19. Crit Care. 2020;24(1):94 doi:10.1186/s13054-020-2828-4

http://www.ncbi.nlm.nih.gov/pubmed/32183864

10.

Lupia

Scabini

Mornese Pinna

Di Perri

De Rosa

FG.

Corcione

. Novel coronavirus (2019-nCoV) outbreak: a new challenge. J Glob Antimicrob Resist. 2019;2020(21):22-27.

11.

Roussel

Giraud-Gatineau

Jimeno

M-T

et al. SARS-CoV-2: fear versus data. Int J Antimicrob Agents. 2020;55(5):105947 doi:10.1016/j.ijantimicag.2020.105947

http://www.ncbi.nlm.nih.gov/pubmed/32201354

12.

Pavli

Tsiodras

Maltezou

. Middle East respiratory syndrome coronavirus (MERS-CoV): prevention in travelers. Travel Med Infect Dis. 2014;12(6 Pt A):602-608.doi:10.1016/j.tmaid.2014.10.006

http://www.ncbi.nlm.nih.gov/pubmed/25457301

13.

Taguchi

. Coronaviruses. Uirusu. 2011;61(2):205-210.doi:10.2222/jsv.61.205

http://www.ncbi.nlm.nih.gov/pubmed/22916567

14.

Qian

Jia

Gao

Zhang

. Isolation and identification of porcine deltacoronavirus and alteration of immunoglobulin transport receptors in the intestinal mucosa of PDCoV-infected piglets. Viruses. 2020;12(1):79 doi:10.3390/v12010079

http://www.ncbi.nlm.nih.gov/pubmed/31936476

15.

Chan

JF-W.

Kok

K-H.

Zhu

et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221-236.doi:10.1080/22221751.2020.1719902

http://www.ncbi.nlm.nih.gov/pubmed/31987001

16.

Zhao

Yao

Wang

et al. A comparative study on the clinical features of coronavirus 2019 (COVID-19) pneumonia with other pneumonias. Clin Infect Dis. 2020;71(15):756-761.doi:10.1093/cid/ciaa247

http://www.ncbi.nlm.nih.gov/pubmed/32161968

17.

Zou

Chen

Zou

Han

Hao

Han

. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-192.doi:10.1007/s11684-020-0754-0

http://www.ncbi.nlm.nih.gov/pubmed/32170560

18.

Zhou

Yang

X-L.

Wang

X-G

et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.doi:10.1038/s41586-020-2012-7

http://www.ncbi.nlm.nih.gov/pubmed/32015507

19.

Zhong

Deng

et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8 doi:10.1038/s41368-020-0074-x

http://www.ncbi.nlm.nih.gov/pubmed/32094336

20.

Qiao

Zhang

. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. J Infect. 2020;80(4):469-496.doi:10.1016/j.jinf.2020.02.013

http://www.ncbi.nlm.nih.gov/pubmed/32092392

21.

Bhatnagar

Murhekar

MV.

Soneja

et al. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use. Indian J Med Res. 2020;151(2 & 3):184-189.doi:10.4103/ijmr.IJMR_502_20

http://www.ncbi.nlm.nih.gov/pubmed/32362644

22.

Cao

Wang

Wen

et al. A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.doi:10.1056/NEJMoa2001282

http://www.ncbi.nlm.nih.gov/pubmed/32187464

23.

Sahraei

Shabani

Shokouhi

Saffaei

. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;105945

24.

Colson

Rolain

J-M.

Raoult

. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55(3):105923 doi:10.1016/j.ijantimicag.2020.105923

http://www.ncbi.nlm.nih.gov/pubmed/32070753

25.

Dong

Gao

. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.doi:10.5582/ddt.2020.01012

http://www.ncbi.nlm.nih.gov/pubmed/32147628

26.

Martinez

. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. 2020;64(5):e00399-20.doi:10.1128/AAC.00399-20

http://www.ncbi.nlm.nih.gov/pubmed/32152082

27.

De Clercq

. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149-150.doi:10.1038/d41573-020-00016-0

http://www.ncbi.nlm.nih.gov/pubmed/32127666

28.

Bose

Adapa

Aeddula

et al. Medical management of COVID-19: evidence and experience. J Clin Med Res. 2020;12(6):329-343.doi:10.14740/jocmr4201

http://www.ncbi.nlm.nih.gov/pubmed/32587649

29.

Liang

Tian

Liu

et al. A promising antiviral candidate drug for the COVID-19 pandemic: a mini-review of remdesivir. Eur J Med Chem. 2020;201:112527 doi:10.1016/j.ejmech.2020.112527

http://www.ncbi.nlm.nih.gov/pubmed/32563812

30.

Khan

Karataş

Rahman

. Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther. 2020;37(6):2575-2579.doi:10.1007/s12325-020-01351-9

http://www.ncbi.nlm.nih.gov/pubmed/32350686

31.

Perico

Benigni

Remuzzi

. Should COVID-19 concern nephrologists? why and to what extent? tthe emerging impasse of angiotensin blockade. Nephron. 2020;144(5):213-221.doi:10.1159/000507305

32.

Gurwitz

. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537-540.doi:10.1002/ddr.21656

http://www.ncbi.nlm.nih.gov/pubmed/32129518

33.

Lai

C-C.

Liu

YH.

Wang

C-Y

et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-412.doi:10.1016/j.jmii.2020.02.012

http://www.ncbi.nlm.nih.gov/pubmed/32173241

34.

Weng

Goel

. Curcumin and colorectal cancer: an update and current perspective on this natural medicine. Semin Cancer Biol. 2020 doi:10.1016/j.semcancer.2020.02.011 20 Feb 2020.http://www.ncbi.nlm.nih.gov/pubmed/32088363

35.

López-Malo

Villarón-Casares

CA.

Alarcón-Jiménez

et al. Curcumin as a therapeutic option in retinal diseases. Antioxidants. 2020;9(1):48 doi:10.3390/antiox9010048

http://www.ncbi.nlm.nih.gov/pubmed/31935797

36.

Chainoglou

Hadjipavlou-Litina

. Curcumin in health and diseases: Alzheimer's disease and curcumin analogues, derivatives, and hybrids. Int J Mol Sci. 2020;21(6):1975 doi:10.3390/ijms21061975

http://www.ncbi.nlm.nih.gov/pubmed/32183162

37.

Meng

Gan

RY.

. Bioactivity, health benefits, and related molecular mechanisms of curcumin: current progress, challenges, and perspectives. Nutrients. 2018;10(10):1553

38.

Kutluay

SB.

Doroghazi

Roemer

ME.

Triezenberg

. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology. 2008;373(2):239-247.doi:10.1016/j.virol.2007.11.028

http://www.ncbi.nlm.nih.gov/pubmed/18191976

39.

Mounce

BC.

Cesaro

Carrau

Vallet

Vignuzzi

. Curcumin inhibits Zika and Chikungunya virus infection by inhibiting cell binding. Antiviral Res. 2017;142:148-157.doi:10.1016/j.antiviral.2017.03.014

http://www.ncbi.nlm.nih.gov/pubmed/28343845

40.

Liu

Yang

Wang

. Curcumin inhibits proliferation of Epstein-Barr virus-associated human nasopharyngeal carcinoma cells by inhibiting EBV nuclear antigen 1 expression. Biomed Res Int. 2019;2019:8592921. doi:10.1155/2019/8592921

http://www.ncbi.nlm.nih.gov/pubmed/31687403

41.

Taher

MM.

Lammering

Hershey

Valerie

. Curcumin inhibits ultraviolet light induced human immunodeficiency virus gene expression. Mol Cell Biochem. 2003;254(1-2):289-297.doi:10.1023/a:1027393719610

http://www.ncbi.nlm.nih.gov/pubmed/14674708

42.

Guo

Xing

Pan

et al. Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis. PLoS One. 2013;8(8):e70565 doi:10.1371/journal.pone.0070565

http://www.ncbi.nlm.nih.gov/pubmed/23936448

43.

Gan

Zhou

Zeng

. Synthesis and antiviral activity of novel 1,4-pentadien-3-one derivatives containing a 1,3,4-thiadiazole moiety. Molecules. 2017;22(4):658 doi:10.3390/molecules22040658

http://www.ncbi.nlm.nih.gov/pubmed/28430149

44.

Wen

C-C.

Kuo

Y-H.

Jan

J-T

et al. Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J Med Chem. 2007;50(17):4087-4095.doi:10.1021/jm070295s

http://www.ncbi.nlm.nih.gov/pubmed/17663539

45.

Yang

XX.

CM.

YF.

Wang

Huang

. Synergistic antiviral effect of curcumin functionalized graphene oxide against respiratory syncytial virus infection. Nanoscale. 2017;9(41):16086-16092.doi:10.1039/C7NR06520E

http://www.ncbi.nlm.nih.gov/pubmed/29034936

46.

Yang

XX.

CM.

Huang

. Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale. 2016;8(5):3040-3048.doi:10.1039/C5NR07918G

http://www.ncbi.nlm.nih.gov/pubmed/26781043

47.

Prasad

Tyagi

. Curcumin and its analogues: a potential natural compound against HIV infection and AIDS. Food Funct. 2015;6(11):3412-3419.doi:10.1039/c5fo00485c

http://www.ncbi.nlm.nih.gov/pubmed/26404185

48.

Vlietinck

AJ.

De Bruyne

Apers

Pieters

. Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med. 1998;64(2):97-109.doi:10.1055/s-2006-957384

http://www.ncbi.nlm.nih.gov/pubmed/9525100

49.

Rocha

FAC.

de Assis

. Curcumin as a potential treatment for COVID-19. Phytother Res. Published online 22 May 2020. doi:10.1002/ptr.6745

32442323

50.

Zahedipour

Hosseini

SA.

Sathyapalan

et al. Potential effects of curcumin in the treatment of COVID-19 infection. Phytother Res. Published online 19 May 2020. doi:10.1002/ptr.6738

32430996

51.

Kandeel

Al-Nazawi

. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Life Sci. 2020;251:117627. doi:10.1016/j.lfs.2020.117627

http://www.ncbi.nlm.nih.gov/pubmed/32251634

52.

Hong

Duan

Yanfang

. Network pharmacology integrated molecular docking reveals the anti-COVID-19 mechanism of Qing-Fei-Da-Yuan granules. Nat Prod Commun. 2020;15(6):1934578X2093421-15.doi:10.1177/1934578X20934219

53.

Peeri

NC.

Shrestha

Rahman

et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned? Int J Epidemiol. 2020;49(3):717-726.doi:10.1093/ije/dyaa033

http://www.ncbi.nlm.nih.gov/pubmed/32086938

54.

Rzymski

Nowicki

. Preventing COVID-19 prejudice in academia. Science. 2020;367(6484):1313. doi:10.1126/science.abb4870

http://www.ncbi.nlm.nih.gov/pubmed/32193314

55.

Shen

Yang

Wang

et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. World J Pediatr. 2020;16(3):223-231.doi:10.1007/s12519-020-00343-7

56.

Goel

Aggarwal

. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919-930.doi:10.1080/01635581.2010.509835

http://www.ncbi.nlm.nih.gov/pubmed/20924967

57.

Sinha

Anderson

DE.

McDonald

SS.

Greenwald

. Cancer risk and diet in India. J Postgrad Med. 2003;49(3):222-228.

58.

Stohs

SJ.

Chen

Ray

SD.

Bucci

LR.

Preuss

. Highly bioavailable forms of curcumin and promising avenues for curcumin-based research and application: a review. Molecules. 2020;25(6):1397 doi:10.3390/molecules25061397

http://www.ncbi.nlm.nih.gov/pubmed/32204372

59.

Luca

SV.

Macovei

Bujor

et al. Bioactivity of dietary polyphenols: the role of metabolites. Crit Rev Food Sci Nutr. 2020;60(4):626-659.doi:10.1080/10408398.2018.1546669

http://www.ncbi.nlm.nih.gov/pubmed/30614249

60.

Jordan

WC.

Drew

. Curcumin—a natural herb with anti-HIV activity. J Natl Med Assoc. 1996;88(6):333

61.

Liu

JP.

Manheimer

Yang

. Herbal medicines for treating HIV infection and AIDS. Cochrane Database Syst Rev. 2005;3:CD003937 doi:10.1002/14651858.CD003937.pub2

http://www.ncbi.nlm.nih.gov/pubmed/16034917

62.

Chen

Liu

Pan

et al. Curcumin attenuates gp120-induced microglial inflammation by inhibiting autophagy via the PI3K pathway. Cell Mol Neurobiol. 2018;38(8):1465-1477.doi:10.1007/s10571-018-0616-3

http://www.ncbi.nlm.nih.gov/pubmed/30155758

63.

Zhao

Yang

Han

et al. Effects of nanoparticle-encapsulated curcumin on HIV-gp120-associated neuropathic pain induced by the P2X₃ receptor in dorsal root ganglia. Brain Res Bull. 2017;135:53-61.doi:10.1016/j.brainresbull.2017.09.011

http://www.ncbi.nlm.nih.gov/pubmed/28962965

64.

Vora

Athar

Sinha

Jha

PC.

Shrivastava

. Binding insight of anti-HIV phytocompounds with prime targets of HIV: a molecular dynamics simulation analysis. Curr HIV Res. 2020;18(2):132-141.doi:10.2174/1570162X18666200129112509

http://www.ncbi.nlm.nih.gov/pubmed/31995010

65.

Vajragupta

Boonchoong

Morris

GM.

Olson

. Active site binding modes of curcumin in HIV-1 protease and integrase. Bioorg Med Chem Lett. 2005;15(14):3364-3368.doi:10.1016/j.bmcl.2005.05.032

http://www.ncbi.nlm.nih.gov/pubmed/15950462

66.

Chai

Yan

Lin

Lumsden

AB.

Yao

Chen

. Curcumin blocks HIV protease inhibitor ritonavir-induced vascular dysfunction in porcine coronary arteries. J Am Coll Surg. 2005;200(6):820-830.doi:10.1016/j.jamcollsurg.2005.02.030

http://www.ncbi.nlm.nih.gov/pubmed/15922191

67.

Sui

Salto

Craik

Ortiz de Montellano

. Inhibition of the HIV-1 and HIV-2 proteases by curcumin and curcumin boron complexes. Bioorg Med Chem. 1993;1(6):415-422.doi:10.1016/s0968-0896(00)82152-5

http://www.ncbi.nlm.nih.gov/pubmed/8087563

68.

Ferreira

VH.

Nazli

Dizzell

SE.

Mueller

Kaushic

. The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. PLoS One. 2015;10(4):e0124903 doi:10.1371/journal.pone.0124903

http://www.ncbi.nlm.nih.gov/pubmed/25856395

69.

Fernández-Sánchez

Baragaño Raneros

Carvajal Palao

et al. DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells. Epigenetics. 2013;8(1):66-78.doi:10.4161/epi.23115

http://www.ncbi.nlm.nih.gov/pubmed/23235109

70.

Bacha

Barrila

Velazquez-Campoy

Leavitt

SA.

Freire

. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry. 2004;43(17):4906-4912.doi:10.1021/bi0361766

http://www.ncbi.nlm.nih.gov/pubmed/15109248

71.

Chen

YW.

Yiu

C-PB.

Wong

K-Y

. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL^pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129.doi:10.12688/f1000research.22457.2

32194944

72.

Nukoolkarn

Lee

VS.

Malaisree

Aruksakulwong

Hannongbua

. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors. J Theor Biol. 2008;254(4):861-867.doi:10.1016/j.jtbi.2008.07.030

http://www.ncbi.nlm.nih.gov/pubmed/18706430

73.

Tai

DYH

. Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore. 2007;36(6):438-443.

In Silico De Novo Curcuminoid Derivatives From the Compound Library of Natural Products Research Laboratories Inhibit COVID-19 3CL pro Activity

Abstract

Keywords

Materials and Methods

Collection of Data Set in Compounds of NPRL

Homology Modeling

Molecular Docking

Results

Construction of COVID-19 3CLpro Homology Models

Molecular Docking

Discussion

Footnotes

Acknowledgments

Declaration of Conflicting Interests

Funding

ORCID iDs

References

Construction of COVID-19 3CL^pro Homology Models